Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
C.J. Hawkey.
Nonsteroidal anti-inflammatory drug gastropathy.
Gastroenterology, 119 (2000), pp. 521-535
[2.]
A. Lanas, L. Rodrigo, J.L. Márquez, E. Bajador, F. Pérez-Roldan, J. Cabrol, et al.
Low frequency of upper gastrointestinal complications in a cohort of high-risk patients taking low-dose aspirin or NSAIDS and omeprazole.
Scand J Gastroenterol, 38 (2003), pp. 693-700
[3.]
A. Lanas.
Economic analysis of strategies in the prevention of non-steroidal anti-inflammatory drug-induced complications in the gastrointestinal tract.
Aliment Pharmacol Ther, 20 (2004), pp. 321-331
[4.]
D.L. Simmons, W. Xie, J.G. Chipman, G.E. Evett.
Prostaglandins, Leukotrienes, Lipoxins and PAF, pp. 67-78x
[5.]
L. Laine.
Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient.
Gastroenterology, 120 (2001), pp. 594-606
[6.]
M.G. Sciulli, M.L. Capone, S. Tacconelli, P. Patrignani.
The future of traditional nonsteroidal antiinflammatory drugs and cyclooxygenase-2 inhibitors in the treatment of inflammation and pain.
Pharmacol Rep, 57 (2005), pp. 66-85
[7.]
J.T. Chen, F. Pucino, B.H. Resman-Targoff.
Celecoxib versus a non-selective NSAID plus proton-pump inhibitor: what are the considerations?.
J Pain Palliat Care Pharmacother, 20 (2006), pp. 11-32
[8.]
G.A. FitzGerald, C. Patrono.
The coxibs, selective inhibitors of cyclooxygenase-2.
N Engl J Med, 345 (2001), pp. 433-442
[9.]
C. Bombardier, L. Laine, A. Reicin, D. Shapiro, R. Burgos-Vargas, B. Davis, et al.
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.
Engl J Med, 343 (2000), pp. 1520-1528
[10.]
F.E. Silverstein, G. Faich, J.L. Goldstein, L.S. Simon, T. Pincus, A. Whelton, et al.
Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
JAMA, 284 (2000), pp. 1247-1255
[11.]
T.J. Schnitzer, G.R. Burmester, E. Mysler, M.C. Hochberg, M. Doherty, E. Ehrsam, et al.
Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial.
Lancet, 364 (2004), pp. 665-674
[12.]
G. Singh, J.G. Fort, J.L. Goldstein, R.A. Levy, P.S. Hanrahan, A.E. Bello, et al.
Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study.
Am J Med, 119 (2006), pp. 255-266
[13.]
D.R. Ramey, D.J. Watson, C. Yu, J.A. Bolognese, S.P. Curtis, A.S. Reicin.
The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis.
Curr Med Res Opin, 21 (2005), pp. 715-722
[14.]
L. Hooper, T.J. Brown, R. Elliott, K. Payne, C. Roberts, D. Symmons.
The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review.
BMJ, 329 (2004), pp. 948-952
[15.]
A. Lanas, L.A. García-Rodríguez, M.T. Arroyo, F. Gomollón, F. Feu, A. González-Pérez, et al.
Risk of upper gastrointestinal ulcer bleeding associated with selectivecyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations.
Gut, 55 (2006), pp. 1731-1738
[16.]
L. Laine, L.G. Connors, A. Reicin, C.J. Hawkey, R. Burgos-Vargas, T.J. Schnitzer, et al.
Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use.
Gastroenterology, 124 (2003), pp. 288-292
[17.]
F.K. Chan, L.C. Hung, B.Y. Suen, J.C. Wu, K.C. Lee, V.K. Leung, et al.
Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis.
N Engl J Med, 347 (2002), pp. 2104-2110
[18.]
J.L. Goldstein, G.M. Eisen, B. Lewis, I.M. Gralnek, S. Zlotnick, J.G. Fort, et al.
Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo.
Clin Gastroenterol Hepatol, 3 (2005), pp. 133-141
[19.]
F.K. Chan, L.C. Hung, B.Y. Suen, V.W. Wong, A.J. Hui, J.C. Wu, et al.
Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial.
Gastroenterology, 127 (2004), pp. 1038-1043
[20.]
K.C. Lai, K.M. Chu, W.M. Hui, B.C. Wong, W.H. Hu, W.M. Wong, et al.
Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
Am J Med, 118 (2005), pp. 1271-1278
[21.]
J.M. Scheiman, N.D. Yeomans, N.J. Talley, N. Vakil, F.K. Chan, Z. Tulassay, et al.
Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors.
Am J Gastroenterol, 101 (2006), pp. 701-710
[22.]
F.K. Chan, V.W. Wong, B.Y. Suen, J.C. Wu, J.Y. Ching, L.C. Hung, et al.
Combination of a cyclo-oxygenase-2 inhibitor and a protonpump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial.
Lancet, 369 (2007), pp. 1621-1626
[23.]
A. Lanas, A. Ferrández.
NSAID-induced gastrointestinal damage: current clinical management and recommendations for prevention.
Chin J Dig Dis, 7 (2006), pp. 127-133
[24.]
R.S. Bresalier, R.S. Sandler, H. Quan, J.A. Bolognese, B. Oxenius, K. Horgan, et al.
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.
N Engl J Med, 352 (2005), pp. 1092-1102
[25.]
J.A. Cairns.
The coxibs and traditional nonsteroidal anti-inflammatory drugs: a current perspective on cardiovascular risks.
Can J Cardiol, 23 (2007), pp. 125-131
[26.]
Food and Drug Administration. Advisory committee briefing document: celecoxib and valdecoxib cardiovascular safety [citado Dic 2007]. Disponible en: www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4090B1_03_Pfizer-Celebrex-Bextra.pdf
[27.]
ADAPT Research Group.
Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT).
PLoS Clin Trials, 1 (2006), pp. 33
[28.]
S.D. Solomon, J.J. McMurray, M.A. Pfeffer, J. Wittes, R. Fowler, P. Finn, et al.
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.
N Engl J Med, 352 (2005), pp. 1071-1080
[29.]
B. Caldwell, S. Aldington, M. Weatherall, P. Shirtcliffe, R. Beasley.
Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis.
J R Soc Med, 99 (2006), pp. 132-140
[30.]
N.A. Nussmeier, A.A. Whelton, M.T. Brown, R.M. Langford, A. Hoeft, J.L. Parlow, et al.
Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery.
N Engl J Med, 352 (2005), pp. 1081-1091
[31.]
C.D. Furberg, B.M. Psaty, G.A. FitzGerald.
Parecoxib, valdecoxib, and cardiovascular risk.
Circulation, 111 (2005), pp. 249
[32.]
C.J. Hawkey, X. Gitton, G. Hoexter, D. Richard, W.M. Weinstein.
Gastrointestinal tolerability of lumiracoxib in patients with osteoarthritis and rheumatoid arthritis.
Clin Gastroenterol Hepatol, 4 (2006), pp. 57-66
[33.]
S.P. Curtis, B. Bockow, C. Fisher, J. Olaleye, A. Compton, A.T. Ko, et al.
Etoricoxib in the treatment of osteoarthritis over 52-weeks: a double-blind, active-comparator controlled trial [NCT0 0242489].
BMC Musculoskelet Disord, 6 (2005), pp. 58
[34.]
J. Hippisley-Cox, C. Coupland.
Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis.
BMJ, 330 (2005), pp. 1366-1373
[35.]
F. Sopena, A. Lanas.
How to advise aspirin use in patients who need NSAIDs.
Curr Pharm Des, 13 (2007), pp. 2248-2260
[36.]
A. Rostom, C. Dubé, G. Lewin, A. Tsertsvadze, N. Barrowman, C. Code, et al.
Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force.
Ann Intern Med, 146 (2007), pp. 376-389
Copyright © 2008. Elsevier España S.L.. Todos los derechos reservados
